Kusunoki Y, Takekoshi Y, Nagasawa S
Department of Pediatrics, School of Medicine, Hokkaido University, Japan.
J Pharmacobiodyn. 1990 Jul;13(7):454-60. doi: 10.1248/bpb1978.13.454.
The terminal complement complex (TCC), consisting of C5b, C6, C7, C8, and C9, contains neoantigens that are absent from the individual native components. Neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. The present study describes production of monoclonal antibodies (MoAbs) against neoantigens of both forms of the TCC using human C9 polymerized in Zn2+ as an immunogen. One of ten MoAbs obtained, MoAb 1B4, reacted with the tubular C9 polymer, but not with either the native or sodium dodecyl sulfate-denatured monomeric C9, as shown by enzyme-linked immunosorbent assay and Western blotting. Moreover, MoAb 1B4 cross-reacted both with MAC and SC5b-9. This suggests MoAb 1B4 recognized a neoantigen in the moiety of C9 polymer in the TCC. MoAb 1B4 will be of value for definitive identification of MAC and for quantitation of SC5b-9 in plasma and urine.
末端补体复合物（TCC）由C5b、C6、C7、C8和C9组成，含有单个天然成分中不存在的新抗原。新抗原存在于膜结合（MAC）和液相（SC5b-9）复合物中。本研究描述了以在Zn2+中聚合的人C9作为免疫原，生产针对两种形式TCC新抗原的单克隆抗体（MoAb）。通过酶联免疫吸附测定和蛋白质印迹法显示，所获得的十种MoAb之一，即MoAb 1B4，与管状C9聚合物反应，但不与天然或十二烷基硫酸钠变性的单体C9反应。此外，MoAb 1B4与MAC和SC5b-9均发生交叉反应。这表明MoAb 1B4识别了TCC中C9聚合物部分的一种新抗原。MoAb 1B4对于MAC的明确鉴定以及血浆和尿液中SC5b-9的定量将具有重要价值。
